Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.

被引：2
|
作者：
Krebs, Matthew
Johnson, Melissa Lynne
Cho, Byoung Chul
Park, Keunchil
Haddish-Berhane, Nahor
Zemlickis, Donna
Mitselos, Anna
Meacle, Francis
Knoblauch, Roland Elmar
Hellemans, Peter
Minchom, Anna Rachel
机构：
[1] Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Manchester, Lancs, England
[2] Manchester Acad Hlth Sci Ctr, Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Janssen R&D, Spring House, PA USA
[7] Janssen R&D, Toronto, ON, Canada
[8] Janssen R&D, Beerse, Belgium
[9] Royal Marsden Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS3150
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3150
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: Preliminary results of a phase IB study.
    Voortman, J
    Smit, EF
    Kuenen, BC
    Pinedo, HM
    van Groeningen, C
    van den Eertwegh, AJ
    Brouwer, D
    van de Velde, H
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 160S - 160S
  • [22] UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES, INCLUDING WALDENSTROM MACROGLOBULINEMIA
    Siegel, D.
    Kaufman, J. L.
    Raje, N.
    Mikhael, J.
    Kapoor, P.
    Treon, S.
    Castillo, J.
    Neuman, L.
    Obreja, M.
    Ghobrial, I.
    HAEMATOLOGICA, 2015, 100 : 461 - 461
  • [23] PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
    Diab, A.
    Hurwitz, M. E.
    Tannir, N.
    Bernatchez, C.
    Haymaker, C.
    Bentebibel, S. E.
    Curti, B. D.
    Wong, M. K. K.
    Gergel, I.
    Tagliaferri, M.
    Zalevsky, J.
    Hoch, U.
    Aung, S.
    Imperiale, M.
    Cho, D.
    Tykodi, S. S.
    Puzanov, I.
    Kluger, H.
    Hwu, P.
    Sznol, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
    Diab, A.
    Hurwitz, M. E.
    Tannir, N.
    Bernatchez, C.
    Haymaker, C.
    Bentebibel, S. E.
    Curti, B. D.
    Wong, M. K. K.
    Gergel, I.
    Tagliaferri, M.
    Zalevsky, J.
    Hoch, U.
    Aung, S.
    Imperiale, M.
    Cho, D.
    Tykodi, S. S.
    Puzanov, I.
    Kluger, H.
    Hwu, P.
    Sznol, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.
    De Mattos-Arruda, Leticia
    Siu, Lillian L.
    Cortes, Javier
    Berge, Yann
    Razak, Albiruni R. A.
    Ahnert, Jordi Rodon
    Cottura, Ewa
    Bedard, Philippe
    Akimov, Mikhail
    Lu, Hong
    Pain, Scott
    Kaag, Audrey
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies
    Olszewski, Adam
    Kahn, David
    Yoo, Brian
    Tan, Joanne B. L.
    Gupta, Vipul K.
    Schuck, Edgar
    Nie, Zhe
    Krilov, Goran
    Wright, D. Hamish
    Weiss, Daniel
    Lachowicz, Jean
    Akinsanya, Karen
    Yin, Wu
    BLOOD, 2023, 142
  • [27] Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma
    Ribas, A.
    Gonzalez, R.
    Drabick, J.
    Kummar, S.
    Agarwala, S.
    Nemunaitis, J.
    Coffman, R.
    Berman, C. J.
    Schmidt, E.
    Chartash, E.
    Guiducci, C.
    Candia, A.
    Janssen, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [29] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [30] A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors
    Yamamoto, Noboru
    Kuboki, Yasutoshi
    Harano, Kenichi
    Koyama, Takafumi
    Kondo, Shunsuke
    Hagiwara, Akiko
    Suzuki, Noriko
    Fujikawa, Ei
    Toyoizumi, Kiichiro
    Mukai, Mayumi
    Doi, Toshihiko
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 376 - 385
12345